Literature DB >> 29577924

The Society of Thoracic Surgeons 2018 Adult Cardiac Surgery Risk Models: Part 2-Statistical Methods and Results.

Sean M O'Brien1, Liqi Feng1, Xia He1, Ying Xian1, Jeffrey P Jacobs2, Vinay Badhwar3, Paul A Kurlansky4, Anthony P Furnary5, Joseph C Cleveland6, Kevin W Lobdell7, Christina Vassileva8, Moritz C Wyler von Ballmoos9, Vinod H Thourani10, J Scott Rankin3, James R Edgerton11, Richard S D'Agostino12, Nimesh D Desai13, Fred H Edwards14, David M Shahian15.   

Abstract

BACKGROUND: The Society of Thoracic Surgeons (STS) uses statistical models to create risk-adjusted performance metrics for Adult Cardiac Surgery Database (ACSD) participants. Because of temporal changes in patient characteristics and outcomes, evolution of surgical practice, and additional risk factors available in recent ACSD versions, completely new risk models have been developed.
METHODS: Using July 2011 to June 2014 ACSD data, risk models were developed for operative mortality, stroke, renal failure, prolonged ventilation, mediastinitis/deep sternal wound infection, reoperation, major morbidity or mortality composite, prolonged postoperative length of stay, and short postoperative length of stay among patients who underwent isolated coronary artery bypass grafting surgery (n = 439,092), aortic or mitral valve surgery (n = 150,150), or combined valve plus coronary artery bypass grafting surgery (n = 81,588). Separate models were developed for each procedure and endpoint except mediastinitis/deep sternal wound infection, which was analyzed in a combined model because of its infrequency. A surgeon panel selected predictors by assessing model performance and clinical face validity of full and progressively more parsimonious models. The ACSD data (July 2014 to December 2016) were used to assess model calibration and to compare discrimination with previous STS risk models.
RESULTS: Calibration in the validation sample was excellent for all models except mediastinitis/deep sternal wound infection, which slightly underestimated risk and will be recalibrated in feedback reports. The c-indices of new models exceeded those of the last published STS models for all populations and endpoints except stroke in valve patients.
CONCLUSIONS: New STS ACSD risk models have generally excellent calibration and discrimination and are well suited for risk adjustment of STS performance metrics.
Copyright © 2018 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29577924     DOI: 10.1016/j.athoracsur.2018.03.003

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  56 in total

Review 1.  Coronary Revascularization in High-Risk Stable Patients With Significant Comorbidities: Challenges in Decision-Making.

Authors:  Joshua Schulman-Marcus; Kellsey Peterson; Riju Banerjee; Sanjay Samy; Neil Yager
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-02-09

Review 2.  Contemporary review in the multi-modality imaging evaluation and management of tricuspid regurgitation.

Authors:  Tom Kai Ming Wang; Shinya Unai; Bo Xu
Journal:  Cardiovasc Diagn Ther       Date:  2021-06

3.  The Evolving Burden of Drug Use Associated Infective Endocarditis in the United States.

Authors:  Arnar Geirsson; Asher Schranz; Oliver Jawitz; Makoto Mori; Liqi Feng; Brittany A Zwischenberger; Alexander Iribarne; Joseph Dearani; Gregory Rushing; Vinay Badhwar; Juan A Crestanello
Journal:  Ann Thorac Surg       Date:  2020-05-06       Impact factor: 4.330

Review 4.  Sex Differences and Similarities in Valvular Heart Disease.

Authors:  Jacqueline T DesJardin; Joanna Chikwe; Rebecca T Hahn; Judy W Hung; Francesca N Delling
Journal:  Circ Res       Date:  2022-02-17       Impact factor: 17.367

5.  Role of Frailty in Identifying Benefit From Transcatheter Versus Surgical Aortic Valve Replacement.

Authors:  Jordan B Strom; Jiaman Xu; Ariela R Orkaby; Changyu Shen; Yang Song; Brian R Charest; Dae H Kim; David J Cohen; Daniel B Kramer; John A Spertus; Robert E Gerszten; Robert W Yeh
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2021-11-15

6.  Prognostic Value of Computed Tomography-Derived Extracellular Volume in TAVR Patients With Low-Flow Low-Gradient Aortic Stenosis.

Authors:  Balaji Tamarappoo; Donghee Han; Jeffrey Tyler; Tarun Chakravarty; Yuka Otaki; Robert Miller; Evann Eisenberg; Siddharth Singh; Takahiro Shiota; Robert Siegel; Jasminka Stegic; Tracy Salseth; Wen Cheng; Damini Dey; Louise Thomson; Daniel Berman; John Friedman; Raj Makkar
Journal:  JACC Cardiovasc Imaging       Date:  2020-10-28

7.  Postoperative Complications Are Not Elevated in Well-Compensated ESRD Patients Undergoing Cardiac Surgery: End-Stage Renal Disease Cardiac Surgery Outcomes.

Authors:  Benjamin R Griffin; Patrick D Kohtz; Michael Bronsert; T Brett Reece; Joseph C Cleveland; David A Fullerton; Sarah Faubel; Muhammad Aftab
Journal:  J Surg Res       Date:  2019-11-27       Impact factor: 2.192

8.  Outcomes of Aortic Valve Replacement for Chronic Aortic Insufficiency: Analysis of the Society of Thoracic Surgeons Database.

Authors:  Christopher T Ryan; Ayman Almousa; Rodrigo Zea-Vera; Qianzi Zhang; Christopher I Amos; Joseph S Coselli; Todd K Rosengart; Ravi K Ghanta
Journal:  Ann Thorac Surg       Date:  2021-04-25       Impact factor: 4.330

9.  Factors Associated With High Resource Use in Elective Adult Cardiac Surgery From 2005 to 2016.

Authors:  Young-Ji Seo; Sohail Sareh; Joseph Hadaya; Yas Sanaiha; Boback Ziaeian; Richard J Shemin; Peyman Benharash
Journal:  Ann Thorac Surg       Date:  2021-03-06       Impact factor: 4.330

10.  High-Risk Committee for Cardiac Surgery Decision-Making: Results From 110 Consecutive Patients.

Authors:  Lauren V Huckaby; Thomas G Gleason; Francis D Ferdinand; Ibrahim Sultan; Danny Chu; Pyongsoo Yoon; Forozan Navid; Siva Venkata; David West; Claudio Lima; Victor Morell; Shangzhen Chen; Floyd Thoma; Sasha Drew; Arman Kilic
Journal:  Ann Thorac Surg       Date:  2020-10-27       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.